Rahul S. Tonk, MD, MBA

Rahul S. Tonk, MD, MBA, discussed his session on dry eye disease at EnVision Summit 2026, and looked ahead at the pipeline of therapies in development.

Tonk, MD, MBA, references updates from TFOS DEWS III that promote standardized screening tools.

Thomas A. Albini, MD; Rahul Tonk, MD, MBA; Alison Bozung, OD, FAAO; and Joseph Allen, OD, FAAO, Dipl ABO, weigh in on what they gained from the conference.

Rahul Tonk, MD, MBA, outlines a session he gave alongside Joseph Allen, OD, FAAO, Dipl ABO, at EyeCon 2025.

A panel of ophthalmologists and optometrists conclude a discussion about dry eye disease by commenting on advances occurring in the field and future expectations for managing patients.

Unique clinical trials and novel products of interest currently under investigation for the treatment of dry eye disease.

Strategies that can help eye care specialists work with patients to establish and stick to treatment plans for dry eye disease.

Types of in-office procedures currently being used by ophthalmologists and optometrists to aid in the treatment of dry eye disease.

Eye care specialists describe when corticosteroid therapy should be considered to treat dry eye disease and describe best practices when treating pre-surgical patients.

The most common types of artificial tears recommended to help manage dry eye disease and the importance of proper use for full benefit.

Eye care professionals discuss their comfort in recommending oral omega-3 fatty acids to help treat dry eye disease.

How to select and discuss sequential therapy with patients who have dry eye disease and set expectations for treatment.

Resources and strategies that can be used to help educate patients about dry eye disease and optimize adherence to therapy.

Criteria that would prompt further evaluation for dry eye disease and the types of tests used to work-up and accurately diagnose the condition.

Eye care professionals explain the impact of unstable tear film and untreated dry eye disease on patient quality of life.

The impact of autoimmune and systemic diseases as well as environmental triggers on the development of dry eye disease.

A panel of ophthalmologists and optometrists begin a discussion on the management of dry eye disease by defining the condition and highlighting common symptoms.